Navigation Links
Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
Date:9/10/2007

Results Show Improvements in RA Signs and Symptoms Compared to Placebo

SEATTLE, Sept. 10 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced preliminary analysis of results from a Phase IIb randomized, double-blind, placebo-controlled, multicenter clinical trial of its TRU-015 product candidate for rheumatoid arthritis (RA). The results indicated that Trubion's TRU-015 product candidate, at well-tolerated dosages, provided statistically significant improvements in RA signs and symptoms compared to placebo at 24 weeks. Trubion is co-developing TRU-015 with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), for the treatment of rheumatoid arthritis.

TRU-015 Phase IIb Clinical Trial Protocol and Results

The Phase IIb randomized, double-blind, placebo-controlled, multicenter clinical trial included 276 patients with rheumatoid arthritis who were also receiving methotrexate as background therapy. Patients in the Phase IIb study were randomized evenly into five groups that received either placebo, 200 mg, 400 mg, 800 mg or 1600 mg of TRU-015.

The study was designed to evaluate the safety and efficacy of a single intravenous infusion of TRU-015 compared to placebo for a 24-week period, with a primary endpoint of improvement on the Disease Activity Score (DAS)-28 scale at 12 weeks, and secondary endpoints including response rates at 24 weeks using American College of Rheumatology (ACR) criteria.

Preliminary analysis i
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 North America Gynecological Devices ... GlobalData,s new report, "North America Gynecological ... data on the North America Gynecological Devices market. ... dollars, volume (in units) and average prices (in ... Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization ...
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 ... significant growth during the last decade due ... environment, natural calamities and technological advancements. This ... strategies within various segments of the ambulance ... as transportation equipment, blood and hemorrhage control ...
(Date:9/17/2014)... 17, 2014  Decision Resources Group finds ... eligible for biologic therapy, only a proportion ... gastroenterologists cite patients, discomfort with biological therapy ... rates, followed by cost-related issues and payer ... biologics, Janssen Biotech,s Remicade and AbbVie,s Humira ...
Breaking Medicine Technology:North America Gynecological Devices Market Outlook to 2020 2North America Gynecological Devices Market Outlook to 2020 3Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3
... 2012  Sensitech Inc., the global leader in cold ... Transport Association (IATA) has deemed Sensitech,s full range ... in compliance with the 53rd edition of the ... published by the United Nations.   The size and ...
... FRANCISCO, April 26, 2012 Onyx Pharmaceuticals, Inc. (Nasdaq: ... Food and Drug Administration,s (FDA) Oncologic Drugs Advisory Committee ... for carfilzomib for the treatment of patients with relapsed ... two prior therapies. ODAC will review carfilzomib at its ...
Cached Medicine Technology:Sensitech Inc. Products Receive Regulatory Compliance Approval from IATA 2Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma 2Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma 3
(Date:9/18/2014)... N-Zyme Scientifics LLC achieved a major developmental milestone ... mere 8 months after company startup. Its novel product ... enzyme used in the “Biologics” industry for discovery and ... pathology on Mass Spec devices. PRIME™ is being sold ... market (PNGase F PRIMETM). N-Zyme is currently evaluating ...
(Date:9/17/2014)... 18, 2014 The global ablation technologies ... 9.6% from 2014 to 2019. Although mature markets (such ... larger shares in the ablation technologies market in 2014, ... highest CAGR of 12.8% in the next five years.Factors ... infrastructure, growing number of hospitals and surgical centers, and ...
(Date:9/17/2014)... 18, 2014 iFitDress.com, a renowned wedding dress ... petite evening dresses . All these outfits are now ... discounted shipping costs. , “iFitDress.com is a professional company ... We are now busy selling our new collection of petite ... an order above $800 can get free shipping. All these ...
(Date:9/17/2014)... 2014 Mercy College is proud to welcome ... of Social and Behavioral Sciences. As dean, she ... the academic mission of the dynamic undergraduate and graduate programs ... honored to join Mercy College. During my first three ... campuses dedicated to the educational mission of the College. ...
(Date:9/17/2014)... Lake City, UT (PRWEB) September 17, 2014 ... Miss America 2015 Kira Kazantsev and ushered in ... need charitable support. As Miss America Organization’s official ... is welcoming Kazantsev as its newest National Goodwill ... her at member Children’s Miracle Network Hospitals across ...
Breaking Medicine News(10 mins):Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:Elegant Petite Evening Dresses Introduced By Renowned Supplier iFitDress.com 2Health News:Mercy College Welcomes New Dean of the School of Social and Behavioral Sciences 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 3
... Sept. 20 Approximately 100,corporate pilots and ... earn,lifesaving certifications provided by the American Heart ... Safety Standdown in Wichita, Kan.,Oct. 22-25. ... event offers safety,training to the business aviation ...
... single dose of Otsukas investigational oral medication tolvaptan, ... in hemodynamics associated with a significant increase in ... (ADHF) who participated in the international trial the ... with HEart failure (ECLIPSE), presented at the late ...
... Inc.,(TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing ... technologies for,the management of cancer, today announced that ... Vincent were elected to the Board of Directors ... 19, 2007. Dr. Burger has been,unanimously elected as ...
... A Florida pharmacy,owner and a Kentucky physician pleaded ... pharmacy business that generated more than,$126 million in ... Assistant Attorney General Alice S. Fisher of the ... the Southern District of,California announced today. Claude ...
... ... Zoo, Chicago, FAIRFAX, Va., Sept. 19 ... heavy vaginal,bleeding caused by uterine fibroids, noncancerous tumors that develop in,the muscular ... of Chicago, IL, and is a 46-year-old menopausal western lowland,gorilla. Doctors have ...
... Event to Take Place Friday February 8th, 2008, ... Inc. of Rancho Mirage, will host its first,annual Gala, ... A. Lopez, Director of Internal Medicine Specialists-Rancho,Mirage. The elegant ... Resort in Rancho Mirage and will begin at 6:00 ...
Cached Medicine News:Health News:MedAire to Provide Medical Training for Bombardier Safety Standdown 2Health News:MedAire to Provide Medical Training for Bombardier Safety Standdown 3Health News:ECLIPSE data on effects of Otsuka's investigational novel treatment, Tolvaptan 2Health News:Lorus Therapeutics announces election of three new Directors and appoints a new Chairman 2Health News:Lorus Therapeutics announces election of three new Directors and appoints a new Chairman 3Health News:Lorus Therapeutics announces election of three new Directors and appoints a new Chairman 4Health News:Doctor and Pharmacy Owner Plead Guilty in Internet Pharmacy Conspiracy 2Health News:Doctor and Pharmacy Owner Plead Guilty in Internet Pharmacy Conspiracy 3Health News:Gorilla Receives State-Of-The-Art Treatment for Uterine Fibroids from Interventional Radiologists 2Health News:Gorilla Receives State-Of-The-Art Treatment for Uterine Fibroids from Interventional Radiologists 3Health News:IMA South American Extravaganza Dinner to Honor Coachella Valley Doctor 2
... high-end microplate reader with outstanding sensitivity and ... Fluorescence Intensity - FRET , Fluorescence Polarization ... , Luminescence , , , ... reader with fastest read times. The ultimate ...
GENios Pro, TECANs advanced, multi-functional injector reader offers simultaneous reagent dispensing and detection for monitoring of fast kinetic reactions...
... Throughput Screening (UHTS), Analyst GT delivers ... for smooth transfer of assays into ... all the detection modalities of Analyst ... polarization, time-resolved fluorescence, luminescence, absorbance, as ...
... a fully automated microplate based multi-detection ... principles:, , Fluorescence Polarization , ... , High-Performance Luminescence (flash and glow) ... is designed for the widest possible ...
Medicine Products: